Skip to main content

Table 2 General health perception, treatment satisfaction, and fatigue

From: Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes

Characteristics

Range

General health perception

 

T1 - best

≥6

T2 - intermediate

5

T3 - worst

≤4

Mean ± SD

4.6 ± 1.3

TSQM scores

 Total

T1 - best

≥81

T2 - intermediate

68–80

T3 - worst

≤67

Mean ± SD

74 ± 16

Effectiveness

T1 - best

≥76

T2 - intermediate

61–75

T3 - worst

≤60

Mean ± SD

71 ± 21

Side effects

T1 - best

100

T2 - intermediate

70–99

T3 - worst

≤69

Mean ± SD

81 ± 26

Convenience

T1 - best

≥81

T2 - intermediate

66–80

T3 - worst

≤65

Mean ± SD

70 ± 17

Global

T1 - best

≥86

T2 - intermediate

71–85

T3 - worst

≤70

Mean ± SD

78 ± 19

PROMIS fatigue T-scores

 

T1 - best

 ≤53

T2 - intermediate

54–60

T3 - worst

 ≥61

Mean ± SD

57 ± 9

  1. Respondents were ranked by their scores and divided into tertiles (T1, T2 and T3) corresponding to best, intermediate, and worst, respectively. GHP was measured on a 1–7 scale (1 = poor health and 7 = excellent health). TSQM transformed scores were measured on a 0–100 scale (0 = worst satisfaction and 100 = perfect satisfaction). Fatigue was assessed using the PROMIS Fatigue Short Form 7a and Parent/Caregiver Proxy respectively ( 29.4 = least fatigue and 83.2 = most fatigue)
  2. GHP General health perception, PROMIS Patient-Reported Outcome Management Information System, SD standard deviation, SCIG subcutaneous immunoglobulin, TSQM Treatment Satisfaction Questionnaire for Medication